NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

May 01, 2018

Jeffrey S. Weber, MD, PhD, the Laura and Isaac Perlmutter Professor of Oncology, co-director of the Melanoma Research Program, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, and a 2016 Giant of Cancer Care® in Melanoma, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

April 24, 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.

April 19, 2018

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, addresses global disparities in cervical cancer.

March 19, 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care® in Melanoma, discusses the side effect profile of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with melanoma.

February 07, 2018

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses misconceptions regarding robotic-assisted bladder surgery.

February 07, 2018

Selective bladder preservation has been suggested as a potential alternative to cystectomy in patients with bladder cancer who have a transitional cell carcinoma pathology.

January 26, 2018

Jeffrey S. Weber, MD, PhD, discusses the future of immunotherapy in the treatment of melanoma.

January 17, 2018

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

December 14, 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

October 26, 2017

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

August 16, 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.

August 08, 2017

Douglas Levine, MD, provides his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.

July 27, 2017

Checkpoint inhibitors against PD-1 and PD-L1 have shown promise, both as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer.

June 13, 2017

Findings from a clinical trial led by a researcher at NYU Langone's Perlmutter Cancer Center helped pave the way for the recent, accelerated approval by the US Food and Drug Administration of a highly effective immunotherapy as first-line treatment for patients with advanced bladder cancer who are not eligible for treatment with standard chemotherapy.

May 22, 2017

Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.

April 19, 2017

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses sequencing challenges as well as emerging agents in the field of ALK-positive non–small cell lung cancer (NSCLC).

April 05, 2017

Leena Gandhi, MD, PhD, discusses emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.

March 22, 2017

Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.

February 23, 2017

Researchers at NYU Langone Medical Center are taking an approach that focuses on the unique metabolic adaptations of pancreatic cancer.

February 14, 2017

Douglas A. Levine, MD, discussed the relationship between EMSY and BRCA, the potential to target EMSY amplified tumors with PARP inhibitors, and the future of ovarian cancer treatment.